<SEC-DOCUMENT>0001171843-24-006772.txt : 20241205
<SEC-HEADER>0001171843-24-006772.hdr.sgml : 20241205
<ACCEPTANCE-DATETIME>20241205163541
ACCESSION NUMBER:		0001171843-24-006772
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20241205
DATE AS OF CHANGE:		20241205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PORTAGE BIOTECH INC.
		CENTRAL INDEX KEY:			0001095435
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275229
		FILM NUMBER:		241529582

	BUSINESS ADDRESS:	
		STREET 1:		CLARENCE THOMAS BUILDING
		STREET 2:		P.O. BOX 4649, ROAD TOWN
		CITY:			TORTOLA
		STATE:			D8
		ZIP:			VG1110
		BUSINESS PHONE:		416-737-7600

	MAIL ADDRESS:	
		STREET 1:		CLARENCE THOMAS BUILDING
		STREET 2:		P.O. BOX 4649, ROAD TOWN
		CITY:			TORTOLA
		STATE:			D8
		ZIP:			VG1110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BONTAN CORP INC
		DATE OF NAME CHANGE:	20030421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DEALCHECK COM INC
		DATE OF NAME CHANGE:	19990921
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>f424b3_120524.htm
<DESCRIPTION>FORM 424B3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Filed Pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Registration No. 333-275229</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>(to Prospectus dated November 7, 2023)</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><B><IMG SRC="logo.jpg" ALT=""></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Portage Biotech Inc.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; background-color: white"><B>481,581 Ordinary Shares underlying Warrants</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 24pt; margin: 0pt 0">This prospectus supplement is being filed to update and supplement the information
contained in the prospectus dated November 7, 2023 (the &ldquo;Prospectus&rdquo;), which forms a part of our Registration Statement on
Form F-1 (Registration No. 333-275229), as amended most recently by the post-effective amendment filed on August 23, 2024, with the information
contained in our current report on Form 6-K, furnished to the Securities and Exchange Commission on December 5, 2024 (the &ldquo;December
5, 2024 Form 6-K&rdquo;). Accordingly, we have attached the December 5, 2024 Form 6-K to this prospectus supplement.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 24pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 24pt; margin: 0pt 0">This prospectus supplement updates and supplements the information in the
Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any
amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency
between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 24pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 24pt; margin: 0pt 0">Our Ordinary Shares are listed on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;)
under the symbol &ldquo;PRTG&rdquo;. On December 5, 2024, the closing sale price of our Ordinary Shares as reported on Nasdaq was $4.07.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>___________________________</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 24pt; margin: 0pt 0"><B>Investing in the securities offered in the Prospectus involves a high
degree of risk. Before making any investment in these securities, you should consider carefully the risks and uncertainties in the section
entitled &ldquo;Risk Factors&rdquo; beginning on page 9 of the Prospectus, and in the other documents that are incorporated by reference
into the Prospectus.</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 24pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 24pt; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state or non-U.S.
regulatory body has approved or disapproved of the securities offered in the Prospectus or passed upon the accuracy or adequacy of the
Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><B>___________________________</B></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>The date of this prospectus supplement is&nbsp;December 5, 2024</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 3pt outset"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>UNITED STATES</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>FORM 6-K</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>For the month of December, 2024</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Commission File Number: <B>001-40086</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>Portage Biotech Inc.</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Translation of registrant&#8217;s name into English)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British
Virgin Islands, VG1110</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Address of principal executive office)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">&#9746; Form 20-F&nbsp;&#9;&#9744; Form 40-F</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; background-color: white">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; background-color: white"><B>INCORPORATION BY REFERENCE</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">This report on Form 6-K (including
any exhibits attached hereto) shall be deemed to be incorporated by reference into the registration statement on Form S-8 (File No. 333-275842)
of Portage Biotech Inc. (including any prospectuses forming a part of such registration statement) and to be a part thereof from the date
on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 3pt outset"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Management Changes</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to the terms of that certain Services Agreement, dated as of December 15, 2021, by
and between Portage Development Services Inc., a wholly-owned subsidiary of Portage Biotech, Inc (the &#8220;Company&#8221;), and Ian
Walters, M.D. (the &#8220;Services Agreement&#8221;), Dr. Walters&#8217;s term as Chief Executive Officer (&#8220;CEO&#8221;) of the Company
will expire and he will cease serving as CEO of the Company, effective as of the close of business on December 14, 2024. A copy of the
Services Agreement is included as Exhibit 10.5 to the Company&#8217;s Annual Report on Form 20-F filed with the U.S. Securities and Exchange
Commission on August 1, 2022.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Board Changes</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">In connection with the foregoing, Dr. Walters is no longer a member
of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;), effective December 4, 2024.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">In addition, Justin Stebbing, M.D., Ph.D., a current member of the
Board, was appointed Chair of the Board.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; background-color: white"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 3pt outset"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; background-color: white"><B></B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; background-color: white"><B>SIGNATURE</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt">Date: December 5, 2024</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white"><B>PORTAGE BIOTECH INC.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font-size: 10pt">By: </TD>
    <TD STYLE="width: 20%; border-bottom: black 1.5pt solid; font-size: 10pt">/s/ Andrea Park</TD>
    <TD STYLE="width: 78%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Andrea Park</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !- +0# 2(  A$! Q$!_\0
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MR6F@*8(NAO)!\[?[H[?4\_2O*[BZFO)GFGE>:5SEI)&+,3[DU])_\*K\+?\
M0)C_ ._C_P"-*OPL\+*P8:1&2#GEW(_G7U>'S/ X6/+2IM?=?\SX+&9)F>.G
MSUZL7Y:V7HK'AGA/X?ZOXPD#6L/DVF<-=3<(/I_>/TKVCPM\)M$\.*DLL7]H
MW@Y\ZX *@_[*]!^IKLX88[>)8HD6.-1A408 'H!3Z\O%YK7Q/NQ?+'LOU9[N
M7Y#A<$E*2YY]W^B_IB !0 !@"N3USQO.;N73/#6G'7M60[9&,GEVEJ?^FTV#
MS_L*&;V'6NKDC6:-D895@5(SC@U%9V5OI]K';VL,=O!&,+'&H51^ KR82C'6
M2O\ D?05(SEI%V_/Y'G@^#O_  E5PE[X^U23Q3*IWII2@P:9"?00 _O"/[TA
M;Z"O0[.RM].M8[:T@BM;>,;4AA0(BCT ' J>BKJ5JE6RD]%TZ+T6Q-.A3HW<
M%J]WNWZO<****P-PJGJ>CV6M6Y@OK6*ZB_NR*#CW!['Z5<HIQDXNZ=F3*,9K
MEDKHYR+1M3\/\Z7=-?V8_P"7&^<EE'I'+U'T;(]Q6MI^JPZAN0*\%PG^LMYA
MM=/P[CW&15VHY+>*62.1T5GC.5;'(_&M95/:?&M>_P#G_5S"%'V7\-Z=O\NW
MIMY$=]I]KJEI):WMM#=VT@VO#.@=&'H0>#7S?\6/V'_#'BQ9KWPE*/#&J')%
MM@O9R'TV]8_^ \?[-?3%%:X?%U\++FHRM_78QQ> PV.AR8B"E^:]'NC\E?B)
M\+?$WPKU<Z?XCTR2R=L^5./FAF'JCC@_S'<"L_PAXWUWP#JR:GX?U2XTN\7^
M.!\!QZ,O1A[$$5^LGB?PGH_C31YM+US3K?5-/E^]!<)N&>Q'<$>HYK#\/_!K
MP+X6Q_9?A+2+5Q_RT^R([_\ ?3 G]:^MCQ%"5+EK4KO\']Y\#4X0J0K\^&K<
ML>E[\R^[\]#R']G?]JJZ^)#V^C^)M#NK74VPD>IV-K(]K,>V_ /ED^OW?ITK
MZ0ID<20QA(T6-!T51@"GU\CB:E*K4<Z4.1=KW/O\'1KT*2IUZGM&NMK?J%%%
M%<IW!5675+.&_@L9+J%+R=6>*W9P)'4=2%ZD"K5>*_%7P\/%7QH\&:6]Y<65
MO<6%X)WMFVR/& "R!OX0PX)'.": .ZO_ (O^"M+OFL[GQ/IL5PIVLGG@[3Z$
MC@5T^G:G9ZQ:)=6-U#>6S_=FMY Z'Z$<5A:?\,O">EZ>+*V\.:8ML!C:UJCD
M_4L"2?J:\W\9>&5^!=_#XQ\+J]MH+3I'K6CHQ,)C8A1-&O\ "RDCIZ^F: /;
MJP/$?C[PYX194UG6K+3I&Y$<TP#D>NWKC\*P/BYXXN_#7A>SCT/;-K>M7$=C
MIQ/*AW_Y:?0#GZD4SP7\%/#WAFW\^^M8]?UN;Y[K4]24322N>I&[.T>P_'-
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4_.O1J* "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
